Evidence map›Paper›PMID 42074034›Full record

ArticleInternational journal of molecular sciences2026

Heterogeneous Intermediate Phenotypes of Cancer Cells with Varying Ki-67-Positivity Rates, Including Histologically HCC-like and NEC-like Cells, in Liver MiNEN.

Sumie Ohni, Yoko Nakanishi, Yukari Hirotani, Ryosuke Toyonaka, Osamu Aramaki, Yukiyasu Okamura, Shinobu Masuda, Makoto Makishima, Mariko Esumi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sumie OhniDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Yoko NakanishiDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Yukari HirotaniDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Ryosuke ToyonakaDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Osamu AramakiDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.ORCID 0000-0003-4264-4384
Yukiyasu OkamuraDivision of Digestive Surgery, Department of Surgery, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Shinobu MasudaDivision of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Makoto MakishimaDivision of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine, Tokyo 173-8610, Japan.ORCID 0000-0002-4630-905X
Mariko EsumiDivision of Biochemistry, Department of Biomedical Sciences, Nihon University School of Medicine, Tokyo 173-8610, Japan.ORCID 0000-0002-4253-2027

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mixed hepatocellular carcinoma (HCC)-neuroendocrine carcinoma (NEC) is a major type of liver mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN). Primary liver NEC, which is very rare, is mostly associated with HCC rather than pure NEC. To characterize the cancer cell heterogeneity of the HCC and NEC components, we comprehensively analyzed the protein expression of three cancer cell biological markers (TERT, Ki-67, and p53) and five differentiation markers (one hepatocyte marker and four neuroendocrine markers) via immunohistochemistry and immunofluorescence using curative resection tissues from three patients with liver MiNEN. TERT/Ki-67/p53 proteins, which are related to cell proliferation and malignancy, were independently expressed in the HCC and NEC components; Ki-67 was highly expressed among the three proteins in both cancer components, and the expression of all three markers was higher in the NEC component than in the HCC component. Despite the intracomponent and intercomponent heterogeneity, the expression signatures of the three markers were similar between the two components, potentially suggesting a common origin of mixed HCC-NEC. An in-depth exploration of intracomponent heterogeneity using differentiation markers revealed multiple intermediate phenotypes of cancer cells, i.e., HCC-like and NEC-like cells, mainly in the HCC component. Histologically NEC-like cells rather than HCC-like cells tended to have an intermediate percentage of Ki-67-positive cells, compared with NEC cells. The spatial distribution of various intermediate cancer cell phenotypes suggests that mixed HCC-NEC may involve the transdifferentiation from HCC cells to NEC cells through the dedifferentiation of HCC.

Indexed as

Carcinoma, HepatocellularCarcinoma, NeuroendocrineKi-67 AntigenLiver NeoplasmsBiomarkers, TumorFemaleHumansMaleMiddle AgedPhenotypeTelomeraseTumor Suppressor Protein p53Biomarkers, TumorKi-67 AntigenTelomeraseTERT protein, humanTumor Suppressor Protein p53cancer cell heterogeneityintermediate phenotypeKi-67mixed hepatocellular carcinoma–neuroendocrine carcinomamixed neuroendocrine–non-neuroendocrine neoplasmp53TERTtransdifferentiation

Identifiers

PMID42074034
PMCPMC13116802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.